| Year |
Citation |
Score |
| 2020 |
Harnoss JM, Le Thomas A, Reichelt M, Guttman O, Wu TD, Marsters SA, Shemorry A, Lawrence DA, Kan D, Segal E, Merchant M, Totpal K, Crocker LM, Mesh K, Dohse M, ... ... Ashkenazi A, et al. IRE1α disruption in triple-negative breast cancer cooperates with anti-angiogenic therapy by reversing ER stress adaptation and remodeling the tumor microenvironment. Cancer Research. PMID 32265225 DOI: 10.1158/0008-5472.Can-19-3108 |
0.372 |
|
| 2020 |
Lam M, Marsters SA, Ashkenazi A, Walter P. Misfolded proteins bind and activate death receptor 5 to induce apoptosis during unresolved endoplasmic reticulum stress. Elife. 9. PMID 31904339 DOI: 10.7554/Elife.52291 |
0.428 |
|
| 2019 |
Shemorry A, Harnoss JM, Guttman O, Marsters SA, Kőműves LG, Lawrence DA, Ashkenazi A. Caspase-mediated cleavage of IRE1 controls apoptotic cell commitment during endoplasmic reticulum stress. Elife. 8. PMID 31453810 DOI: 10.7554/Elife.47084 |
0.369 |
|
| 2019 |
Harnoss JM, Le Thomas A, Shemorry A, Marsters SA, Lawrence DA, Lu M, Chen YA, Qing J, Totpal K, Kan D, Segal E, Merchant M, Reichelt M, Ackerly Wallweber H, Wang W, ... ... Ashkenazi A, et al. Disruption of IRE1α through its kinase domain attenuates multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America. PMID 31371506 DOI: 10.1073/Pnas.1906999116 |
0.331 |
|
| 2019 |
Yang Y, Yeh SH, Madireddi S, Matochko WL, Gu C, Pacheco Sanchez P, Ultsch M, de Leon Boenig G, Harris SF, Leonard B, Scales SJ, Zhu J, Christensen E, Hang JQ, Brezski RJ, ... ... Ashkenazi A, et al. Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members. Mabs. PMID 31156033 DOI: 10.1080/19420862.2019.1625662 |
0.406 |
|
| 2019 |
Lam M, Marsters SA, Ashkenazi A, Walter P. Author response: Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress Elife. DOI: 10.7554/Elife.52291.Sa2 |
0.397 |
|
| 2019 |
Shemorry A, Harnoss JM, Guttman O, Marsters SA, Kőműves LG, Lawrence DA, Ashkenazi A. Author response: Caspase-mediated cleavage of IRE1 controls apoptotic cell commitment during endoplasmic reticulum stress Elife. DOI: 10.7554/Elife.47084.015 |
0.336 |
|
| 2018 |
Chang TK, Lawrence DA, Lu M, Tan J, Harnoss JM, Marsters SA, Liu P, Sandoval W, Martin SE, Ashkenazi A. Coordination between Two Branches of the Unfolded Protein Response Determines Apoptotic Cell Fate. Molecular Cell. 71: 629-636.e5. PMID 30118681 DOI: 10.1016/J.Molcel.2018.06.038 |
0.381 |
|
| 2018 |
Lam M, Lawrence DA, Ashkenazi A, Walter P. Confirming a critical role for death receptor 5 and caspase-8 in apoptosis induction by endoplasmic reticulum stress. Cell Death and Differentiation. PMID 29991746 DOI: 10.1038/S41418-018-0155-Y |
0.399 |
|
| 2017 |
Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nature Reviews. Drug Discovery. PMID 28209992 DOI: 10.1038/Nrd.2016.253 |
0.375 |
|
| 2016 |
Zuch de Zafra CL, Ashkenazi A, Darbonne WC, Cheu M, Totpal K, Ortega S, Flores H, Walker MD, Kabakoff B, Lum BL, Mounho-Zamora BJ, Marsters SA, Dybdal NO. Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey. Cell Death & Disease. 7: e2338. PMID 27512959 DOI: 10.1038/Cddis.2016.241 |
0.403 |
|
| 2016 |
Anania VG, Yu K, Gnad F, Pferdehirt RR, Li H, Ma T, Jeon D, Fortelny N, Forrest W, Ashkenazi A, Overall CM, Lill JR. Uncovering a dual regulatory role for caspases during endoplasmic reticulum stress-induced cell death. Molecular & Cellular Proteomics : McP. PMID 27125827 DOI: 10.1074/Mcp.M115.055376 |
0.349 |
|
| 2015 |
Nair PM, Ngu H, Torres E, Marsters S, Lawrence DA, Stephan JP, Komuves L, Ashkenazi A. Membrane display and functional analysis of juxtacrine ligand-receptor signaling. Biotechniques. 59: 231-40. PMID 26458551 DOI: 10.2144/000114342 |
0.406 |
|
| 2015 |
Yin Y, Djakovic S, Marsters S, Tien J, Peng J, Tremayne J, Lee G, Neve RM, Wu Y, Merchant M, Ashkenazi A, Carter PJ. Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Anti-tumor Activity. Molecular Cancer Therapeutics. PMID 26269606 DOI: 10.1158/1535-7163.Mct-14-1050 |
0.691 |
|
| 2015 |
Chen TT, Filvaroff E, Peng J, Marsters S, Jubb A, Koeppen H, Merchant M, Ashkenazi A. MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation. Ebiomedicine. 2: 406-20. PMID 26137585 DOI: 10.1016/J.Ebiom.2015.03.021 |
0.33 |
|
| 2015 |
Nair PM, Flores H, Gogineni A, Marsters S, Lawrence DA, Kelley RF, Ngu H, Sagolla M, Komuves L, Bourgon R, Settleman J, Ashkenazi A. Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proceedings of the National Academy of Sciences of the United States of America. 112: 5679-84. PMID 25902490 DOI: 10.1073/Pnas.1418962112 |
0.437 |
|
| 2015 |
Petersen SL, Chen TT, Lawrence DA, Marsters SA, Gonzalvez F, Ashkenazi A. TRAF2 is a biologically important necroptosis suppressor. Cell Death and Differentiation. PMID 25882049 DOI: 10.1038/Cdd.2015.35 |
0.428 |
|
| 2015 |
Ashkenazi A. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. The Journal of Clinical Investigation. 125: 487-9. PMID 25642709 DOI: 10.1172/Jci80420 |
0.457 |
|
| 2014 |
Ashkenazi A, Salvesen G. Regulated cell death: signaling and mechanisms. Annual Review of Cell and Developmental Biology. 30: 337-56. PMID 25150011 DOI: 10.1146/Annurev-Cellbio-100913-013226 |
0.414 |
|
| 2014 |
Ashkenazi A, Wells JA, Yuan J. Methods in Enzymology. Regulated cell death part B--necroptotic, autophagic and other non-apoptotic mechanisms. Preface. Methods in Enzymology. 545: xiii. PMID 25065895 DOI: 10.1016/B978-0-12-801430-1.10000-9 |
0.332 |
|
| 2014 |
Lu M, Lawrence DA, Marsters S, Acosta-Alvear D, Kimmig P, Mendez AS, Paton AW, Paton JC, Walter P, Ashkenazi A. Cell death. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science (New York, N.Y.). 345: 98-101. PMID 24994655 DOI: 10.1126/Science.1254312 |
0.385 |
|
| 2014 |
Ashkenazi A, Yuan J, Wells JA. Regulated cell death part A: apoptotic mechanisms. Preface. Methods in Enzymology. 544: xv. PMID 24974300 DOI: 10.1016/B978-0-12-417158-9.10000-7 |
0.361 |
|
| 2014 |
Nair P, Lu M, Petersen S, Ashkenazi A. Apoptosis initiation through the cell-extrinsic pathway. Methods in Enzymology. 544: 99-128. PMID 24974288 DOI: 10.1016/B978-0-12-417158-9.00005-4 |
0.455 |
|
| 2014 |
Fairbrother WJ, Ashkenazi A. Designer proteins to trigger cell death. Cell. 157: 1506-8. PMID 24949963 DOI: 10.1016/J.Cell.2014.06.010 |
0.314 |
|
| 2014 |
Lu M, Marsters S, Ye X, Luis E, Gonzalez L, Ashkenazi A. E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. Molecular Cell. 54: 987-98. PMID 24882208 DOI: 10.1016/J.Molcel.2014.04.029 |
0.402 |
|
| 2014 |
Newton K, Hildebrand JM, Shen Z, Rodriguez D, Alvarez-Diaz S, Petersen S, Shah S, Dugger DL, Huang C, Auwerx J, Vandenabeele P, Green DR, Ashkenazi A, Dixit VM, Kaiser WJ, et al. Is SIRT2 required for necroptosis? Nature. 506: E4-6. PMID 24572428 DOI: 10.1038/Nature13024 |
0.326 |
|
| 2014 |
Wilson C, Pham T, Ye X, Lin E, Chan S, McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, Ashkenazi A, Settleman J. Abstract 693: AXL tyrosine kinase inhibition selectively sensitizes mesenchymal cancer cells to antimitotic agents Cancer Research. 74: 693-693. DOI: 10.1158/1538-7445.Am2014-693 |
0.336 |
|
| 2013 |
Chaudhuri A, Wilson NS, Yang B, Paler Martinez A, Liu J, Zhu C, Bricker N, Couto S, Modrusan Z, French D, Cupp J, Ashkenazi A. Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages. Immunology and Cell Biology. 91: 451-60. PMID 23817579 DOI: 10.1038/Icb.2013.27 |
0.305 |
|
| 2013 |
Lim B, Scicchitano A, Beachler C, Gusani N, Sarwani N, Yang Z, Staveley-O'Carroll K, Ashkenazi A, Portera C, El-Deiry WS. FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biology & Therapy. 14: 711-9. PMID 23792567 DOI: 10.4161/Cbt.25310 |
0.319 |
|
| 2013 |
Gust KM, McConkey DJ, Awrey S, Hegarty PK, Qing J, Bondaruk J, Ashkenazi A, Czerniak B, Dinney CP, Black PC. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Molecular Cancer Therapeutics. 12: 1245-54. PMID 23657946 DOI: 10.1158/1535-7163.Mct-12-1150 |
0.353 |
|
| 2013 |
Ogasawara A, Tinianow JN, Vanderbilt AN, Gill HS, Yee S, Flores JE, Williams SP, Ashkenazi A, Marik J. ImmunoPET imaging of phosphatidylserine in pro-apoptotic therapy treated tumor models. Nuclear Medicine and Biology. 40: 15-22. PMID 23062948 DOI: 10.1016/J.Nucmedbio.2012.09.001 |
0.398 |
|
| 2013 |
Ye X, Yue P, Patel R, Modrusan Z, Settleman J, Ashkenazi A, Yauch RL. Abstract 4463: Activation of FGFR signaling as a mechanism of acquired resistance to erlotinib in EGFR-mutant lung cancer associated with an EMT. Cancer Research. 73: 4463-4463. DOI: 10.1158/1538-7445.Am2013-4463 |
0.317 |
|
| 2012 |
Gonzalvez F, Lawrence D, Yang B, Yee S, Pitti R, Marsters S, Pham VC, Stephan JP, Lill J, Ashkenazi A. TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Molecular Cell. 48: 888-99. PMID 23142077 DOI: 10.1016/J.Molcel.2012.09.031 |
0.431 |
|
| 2012 |
Du X, Wang QR, Chan E, Merchant M, Liu J, French D, Ashkenazi A, Qing J. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth. Cancer Research. 72: 5843-55. PMID 23019225 DOI: 10.1158/0008-5472.Can-12-1329 |
0.398 |
|
| 2012 |
Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Molecular Cancer Therapeutics. 11: 2541-6. PMID 22914439 DOI: 10.1158/1535-7163.Mct-12-0358 |
0.354 |
|
| 2012 |
Wilson NS, Yang A, Yang B, Couto S, Stern H, Gogineni A, Pitti R, Marsters S, Weimer RM, Singh M, Ashkenazi A. Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell. 22: 80-90. PMID 22789540 DOI: 10.1016/J.Ccr.2012.05.014 |
0.39 |
|
| 2012 |
French DM, Lin BC, Wang M, Adams C, Shek T, Hötzel K, Bolon B, Ferrando R, Blackmore C, Schroeder K, Rodriguez LA, Hristopoulos M, Venook R, Ashkenazi A, Desnoyers LR. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. Plos One. 7: e36713. PMID 22615798 DOI: 10.1371/Journal.Pone.0036713 |
0.314 |
|
| 2012 |
Pham VC, Pitti R, Anania VG, Bakalarski CE, Bustos D, Jhunjhunwala S, Phung QT, Yu K, Forrest WF, Kirkpatrick DS, Ashkenazi A, Lill JR. Complementary proteomic tools for the dissection of apoptotic proteolysis events. Journal of Proteome Research. 11: 2947-54. PMID 22432722 DOI: 10.1021/Pr300035K |
0.387 |
|
| 2012 |
Kasubhai SM, Bendell JC, Kozloff M, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC. Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 30: 3543-3543. DOI: 10.1200/Jco.2012.30.15_Suppl.3543 |
0.324 |
|
| 2011 |
Chaudhuri A, Xie MH, Yang B, Mahapatra K, Liu J, Marsters S, Bodepudi S, Ashkenazi A. Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET. The Journal of Biological Chemistry. 286: 32762-74. PMID 21784853 DOI: 10.1074/Jbc.M111.239384 |
0.329 |
|
| 2011 |
Ikner A, Ashkenazi A. TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. The Journal of Biological Chemistry. 286: 21546-54. PMID 21525013 DOI: 10.1074/Jbc.M110.203745 |
0.441 |
|
| 2011 |
Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell. 145: 92-103. PMID 21458669 DOI: 10.1016/J.Cell.2011.02.023 |
0.346 |
|
| 2011 |
Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, ... ... Ashkenazi A, et al. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell. 19: 101-13. PMID 21251615 DOI: 10.1016/J.Ccr.2010.11.012 |
0.438 |
|
| 2011 |
Kozloff M, Messersmith WA, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC, Wainberg ZA. Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 29: 3552-3552. DOI: 10.1200/Jco.2012.30.15_Suppl.3552 |
0.317 |
|
| 2011 |
Du X, Li H, Ingalla E, Ross S, French D, Tien J, Ashkenazi A, Qing J. Abstract C63: Targeting FGFR3 with monoclonal antibody impairs bladder cancer growth in vivo. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C63 |
0.349 |
|
| 2010 |
Bagri A, Ashkenazi A. UNCovering the molecular machinery of dependence receptor signaling. Molecular Cell. 40: 851-3. PMID 21172648 DOI: 10.1016/J.Molcel.2010.12.015 |
0.344 |
|
| 2010 |
Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Current Opinion in Cell Biology. 22: 837-44. PMID 20813513 DOI: 10.1016/J.Ceb.2010.08.001 |
0.418 |
|
| 2010 |
Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 29: 4752-65. PMID 20531300 DOI: 10.1038/Onc.2010.221 |
0.462 |
|
| 2010 |
Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2839-46. PMID 20458040 DOI: 10.1200/Jco.2009.25.1991 |
0.442 |
|
| 2010 |
Stern HM, Padilla M, Wagner K, Amler L, Ashkenazi A. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1587-96. PMID 20179215 DOI: 10.1158/1078-0432.Ccr-09-3108 |
0.328 |
|
| 2010 |
Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1256-63. PMID 20145186 DOI: 10.1158/1078-0432.Ccr-09-1267 |
0.391 |
|
| 2010 |
Eimon PM, Ashkenazi A. The zebrafish as a model organism for the study of apoptosis. Apoptosis : An International Journal On Programmed Cell Death. 15: 331-49. PMID 20033783 DOI: 10.1007/S10495-009-0432-9 |
0.388 |
|
| 2009 |
Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, Scheer JM, Ashkenazi A, Gould SE, Fairbrother WJ, Vucic D. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. The Journal of Biological Chemistry. 284: 34553-60. PMID 19854829 DOI: 10.1074/Jbc.M109.040139 |
0.486 |
|
| 2009 |
Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, Ashkenazi A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell. 137: 721-35. PMID 19427028 DOI: 10.1016/J.Cell.2009.03.015 |
0.417 |
|
| 2009 |
Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, ... ... Ashkenazi A, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. The Journal of Clinical Investigation. 119: 1216-29. PMID 19381019 DOI: 10.1172/Jci38017 |
0.413 |
|
| 2009 |
Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nature Immunology. 10: 348-55. PMID 19295631 DOI: 10.1038/Ni.1714 |
0.375 |
|
| 2008 |
Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, Lawrence D, Zheng Z, Koeppen H, Stern H, Schwall R, Ashkenazi A. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7733-40. PMID 19047100 DOI: 10.1158/1078-0432.Ccr-08-0670 |
0.366 |
|
| 2008 |
Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nature Reviews. Drug Discovery. 7: 1001-12. PMID 18989337 DOI: 10.1038/Nrd2637 |
0.478 |
|
| 2008 |
Shang Y, Mao Y, Batson J, Scales SJ, Phillips G, Lackner MR, Totpal K, Williams S, Yang J, Tang Z, Modrusan Z, Tan C, Liang WC, Tsai SP, Vanderbilt A, ... ... Ashkenazi A, et al. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Molecular Cancer Therapeutics. 7: 2599-608. PMID 18790743 DOI: 10.1158/1535-7163.Mct-07-2401 |
0.383 |
|
| 2008 |
Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3621-30. PMID 18640940 DOI: 10.1200/Jco.2007.15.7198 |
0.466 |
|
| 2008 |
Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. The Journal of Clinical Investigation. 118: 1979-90. PMID 18523647 DOI: 10.1172/Jci34359 |
0.431 |
|
| 2008 |
Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine & Growth Factor Reviews. 19: 325-31. PMID 18495520 DOI: 10.1016/J.Cytogfr.2008.04.001 |
0.473 |
|
| 2008 |
Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death and Differentiation. 15: 751-61. PMID 18219321 DOI: 10.1038/Sj.Cdd.4402306 |
0.332 |
|
| 2008 |
Desnoyers LR, Pai R, Ferrando RE, Hötzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, Ashkenazi A, French DM. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 27: 85-97. PMID 17599042 DOI: 10.1038/Sj.Onc.1210623 |
0.347 |
|
| 2008 |
Ashkenazi A, Wagner K, Punnnoose E, Lawrence D, Pitti R, Amler L. Identification of potentially predictive biomarkers for tumor sensitivity to proapoptotic receptor agonists Journal of Clinical Oncology. 26: 14505-14505. DOI: 10.1200/Jco.2008.26.15_Suppl.14505 |
0.457 |
|
| 2007 |
Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, ... Ashkenazi A, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nature Medicine. 13: 1070-7. PMID 17767167 DOI: 10.1038/Nm1627 |
0.393 |
|
| 2007 |
Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP, Gogineni A, Cole MJ, Yee SF, Ross S, Ashkenazi A. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood. 110: 4037-46. PMID 17724141 DOI: 10.1182/Blood-2007-02-076075 |
0.453 |
|
| 2007 |
Naumann U, Bähr O, Wolburg H, Altenberend S, Wick W, Liston P, Ashkenazi A, Weller M. Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. Gene Therapy. 14: 147-61. PMID 16957768 DOI: 10.1038/Sj.Gt.3302845 |
0.328 |
|
| 2007 |
Yee L, Fanale M, Dimick K, Calvert S, Robins C, Ing J, Novotny W, Ashkenazi A, Burris H. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma Journal of Clinical Oncology. 25: 8078-8078. DOI: 10.1200/Jco.2007.25.18_Suppl.8078 |
0.437 |
|
| 2007 |
Naumann U, Bähr O, Wolburg H, Altenberend S, Wick W, Liston P, Ashkenazi A, Weller M. Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice (Gene Therapy (2007) vol. 14 (147-161) 10.1038/sj.gt.3302845) Gene Therapy. 14: 1434-1437. DOI: 10.1038/Sj.Gt.3303002 |
0.323 |
|
| 2006 |
Eimon PM, Kratz E, Varfolomeev E, Hymowitz SG, Stern H, Zha J, Ashkenazi A. Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death and Differentiation. 13: 1619-30. PMID 16888647 DOI: 10.1038/Sj.Cdd.4402015 |
0.459 |
|
| 2006 |
Kratz E, Eimon PM, Mukhyala K, Stern H, Zha J, Strasser A, Hart R, Ashkenazi A. Functional characterization of the Bcl-2 gene family in the zebrafish. Cell Death and Differentiation. 13: 1631-40. PMID 16888646 DOI: 10.1038/Sj.Cdd.4402016 |
0.333 |
|
| 2006 |
Li B, Russell SJ, Compaan DM, Totpal K, Marsters SA, Ashkenazi A, Cochran AG, Hymowitz SG, Sidhu SS. Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. Journal of Molecular Biology. 361: 522-36. PMID 16859704 DOI: 10.1016/J.Jmb.2006.06.042 |
0.432 |
|
| 2006 |
Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Mazière AM, Klumperman J, Arnott D, Pham V, Scheller RH, Ashkenazi A. Death-receptor activation halts clathrin-dependent endocytosis. Proceedings of the National Academy of Sciences of the United States of America. 103: 10283-8. PMID 16801533 DOI: 10.1073/Pnas.0604044103 |
0.441 |
|
| 2005 |
Hymowitz SG, Ashkenazi A. Toward small-molecule agonists of TNF receptors. Nature Chemical Biology. 1: 353-4. PMID 16370368 DOI: 10.1038/Nchembio1205-353 |
0.352 |
|
| 2005 |
Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. The Journal of Biological Chemistry. 280: 40599-608. PMID 16227629 DOI: 10.1074/Jbc.M509560200 |
0.392 |
|
| 2005 |
Cretney E, McQualter JL, Kayagaki N, Yagita H, Bernard CC, Grewal IS, Ashkenazi A, Smyth MJ. TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunology and Cell Biology. 83: 511-9. PMID 16174101 DOI: 10.1111/J.1440-1711.2005.01358.X |
0.358 |
|
| 2005 |
Sharp DA, Lawrence DA, Ashkenazi A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. The Journal of Biological Chemistry. 280: 19401-9. PMID 15760909 DOI: 10.1074/Jbc.M413962200 |
0.426 |
|
| 2005 |
Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. The Journal of Biological Chemistry. 280: 2205-12. PMID 15520016 DOI: 10.1074/Jbc.M410660200 |
0.479 |
|
| 2004 |
Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, Bedi A. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Research. 64: 9105-14. PMID 15604280 DOI: 10.1158/0008-5472.Can-04-2488 |
0.374 |
|
| 2004 |
Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Research. 64: 4900-5. PMID 15256461 DOI: 10.1158/0008-5472.Can-04-0408 |
0.419 |
|
| 2004 |
Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Current Opinion in Pharmacology. 4: 333-9. PMID 15251125 DOI: 10.1016/J.Coph.2004.02.006 |
0.452 |
|
| 2004 |
Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell. 116: 491-7. PMID 14980217 DOI: 10.1016/S0092-8674(04)00166-7 |
0.392 |
|
| 2004 |
Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, Olsson C, Tom L, Erickson S, French D, Schow P, Grewal IS, Ashkenazi A. APRIL-deficient mice have normal immune system development. Molecular and Cellular Biology. 24: 997-1006. PMID 14729948 DOI: 10.1128/Mcb.24.3.997-1006.2004 |
0.378 |
|
| 2003 |
Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine & Growth Factor Reviews. 14: 337-48. PMID 12787570 DOI: 10.1016/S1359-6101(03)00029-7 |
0.49 |
|
| 2003 |
Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert R, Lawrence D, Sherwood S, DeForge L, Gaudreault J, Keller G, Sliwkowski M, Ashkenazi A, Presta L. Design, construction, and in vitro analyses of multivalent antibodies. Journal of Immunology (Baltimore, Md. : 1950). 170: 4854-61. PMID 12728922 DOI: 10.4049/Jimmunol.170.9.4854 |
0.364 |
|
| 2003 |
LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death and Differentiation. 10: 66-75. PMID 12655296 DOI: 10.1038/Sj.Cdd.4401187 |
0.474 |
|
| 2002 |
Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Reviews. Cancer. 2: 420-30. PMID 12189384 DOI: 10.1038/Nrc821 |
0.438 |
|
| 2002 |
Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA, Mitsiades N. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. The American Journal of Pathology. 161: 643-54. PMID 12163389 DOI: 10.1016/S0002-9440(10)64220-4 |
0.433 |
|
| 2002 |
LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nature Medicine. 8: 274-81. PMID 11875499 DOI: 10.1038/Nm0302-274 |
0.395 |
|
| 2001 |
Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, Gazdar A, Blenis J, Arnott D, Ashkenazi A. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. The Journal of Biological Chemistry. 276: 46639-46. PMID 11583996 DOI: 10.1074/Jbc.M105102200 |
0.426 |
|
| 2001 |
Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, Grewal IS. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nature Immunology. 2: 632-7. PMID 11429548 DOI: 10.1038/89782 |
0.344 |
|
| 2001 |
Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, Ashkenazi A, Kim KJ. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. Journal of Immunology (Baltimore, Md. : 1950). 166: 4891-8. PMID 11290766 DOI: 10.4049/Jimmunol.166.8.4891 |
0.454 |
|
| 2001 |
Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A, Weller M. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Research. 61: 2759-65. PMID 11289159 |
0.303 |
|
| 2000 |
Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Current Biology : Cb. 10: 785-8. PMID 10898980 DOI: 10.1016/S0960-9822(00)00566-2 |
0.392 |
|
| 2000 |
Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 12: 611-20. PMID 10894161 DOI: 10.1016/S1074-7613(00)80212-5 |
0.466 |
|
| 2000 |
Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi A, Dixit VM. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nature Immunology. 1: 37-41. PMID 10881172 DOI: 10.1038/76889 |
0.357 |
|
| 2000 |
Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, de Vos AM, Kelley RF. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry. 39: 633-40. PMID 10651627 DOI: 10.1021/Bi992242L |
0.406 |
|
| 1999 |
Roth W, Isenmann S, Naumann U, Kügler S, Bähr M, Dichgans J, Ashkenazi A, Weller M. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochemical and Biophysical Research Communications. 265: 479-83. PMID 10558893 DOI: 10.1006/Bbrc.1999.1693 |
0.354 |
|
| 1999 |
Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A, de Vos AM. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Molecular Cell. 4: 563-71. PMID 10549288 DOI: 10.1016/S1097-2765(00)80207-5 |
0.406 |
|
| 1999 |
Marsters SA, Pitti RA, Sheridan JP, Ashkenazi A. Control of apoptosis signaling by Apo2 ligand. Recent Progress in Hormone Research. 54: 225-34. PMID 10548878 |
0.391 |
|
| 1999 |
Johnsen AC, Haux J, Steinkjer B, Nonstad U, Egeberg K, Sundan A, Ashkenazi A, Espevik T. Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine. 11: 664-72. PMID 10479402 DOI: 10.1006/Cyto.1999.0489 |
0.338 |
|
| 1999 |
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. The Journal of Clinical Investigation. 104: 155-62. PMID 10411544 DOI: 10.1172/Jci6926 |
0.405 |
|
| 1999 |
Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Current Opinion in Cell Biology. 11: 255-60. PMID 10209153 DOI: 10.1016/S0955-0674(99)80034-9 |
0.454 |
|
| 1999 |
Gurney AL, Marsters SA, Huang RM, Pitti RM, Mark DT, Baldwin DT, Gray AM, Dowd AD, Brush AD, Heldens AD, Schow AD, Goddard AD, Wood WI, Baker KP, Godowski PJ, ... Ashkenazi A, et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Current Biology : Cb. 9: 215-8. PMID 10074428 DOI: 10.1016/S0960-9822(99)80093-1 |
0.416 |
|
| 1998 |
Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, ... ... Ashkenazi A, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 396: 699-703. PMID 9872321 DOI: 10.1038/25387 |
0.454 |
|
| 1998 |
Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science (New York, N.Y.). 281: 1305-8. PMID 9721089 DOI: 10.1126/Science.281.5381.1305 |
0.418 |
|
| 1998 |
Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? Febs Letters. 427: 124-8. PMID 9613612 DOI: 10.1016/S0014-5793(98)00409-8 |
0.447 |
|
| 1998 |
Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashkenazi A. Identification of a ligand for the death-domain-containing receptor Apo3. Current Biology : Cb. 8: 525-8. PMID 9560343 DOI: 10.1016/S0960-9822(98)70204-0 |
0.447 |
|
| 1997 |
Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Current Biology : Cb. 7: 1003-6. PMID 9382840 DOI: 10.1016/S0960-9822(06)00422-2 |
0.47 |
|
| 1997 |
Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (New York, N.Y.). 277: 818-21. PMID 9242611 DOI: 10.1126/Science.277.5327.818 |
0.465 |
|
| 1997 |
Ashkenazi A, Chamow SM. Immunoadhesins as research tools and therapeutic agents. Current Opinion in Immunology. 9: 195-200. PMID 9099788 DOI: 10.1016/S0952-7915(97)80135-5 |
0.321 |
|
| 1996 |
Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, Bauer KD, Ashkenazi A. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Current Biology : Cb. 6: 1669-76. PMID 8994832 DOI: 10.1016/S0960-9822(02)70791-4 |
0.428 |
|
| 1996 |
Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Current Biology : Cb. 6: 750-2. PMID 8793301 DOI: 10.1016/S0960-9822(09)00456-4 |
0.422 |
|
| 1996 |
Chamow SM, Ashkenazi A. Immunoadhesins: principles and applications. Trends in Biotechnology. 14: 52-60. PMID 8746117 DOI: 10.1016/0167-7799(96)80921-8 |
0.308 |
|
| 1996 |
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. The Journal of Biological Chemistry. 271: 12687-90. PMID 8663110 DOI: 10.1074/Jbc.271.22.12687 |
0.391 |
|
| 1995 |
Oksenberg D, Havlik S, Peroutka SJ, Ashkenazi A. The third intracellular loop of the 5-hydroxytryptamine2A receptor determines effector coupling specificity. Journal of Neurochemistry. 64: 1440-7. PMID 7891070 DOI: 10.1046/J.1471-4159.1995.64041440.X |
0.344 |
|
| 1995 |
Ashkenazi A, Chamow SM. Immunoadhesins: An Alternative to Human Monoclonal Antibodies Methods. 8: 104-115. DOI: 10.1006/Meth.1995.9996 |
0.341 |
|
| 1994 |
Jin H, Yang R, Marsters SA, Bunting SA, Wurm FM, Chamow SM, Ashkenazi A. Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody. The Journal of Infectious Diseases. 170: 1323-6. PMID 7963738 DOI: 10.1093/Infdis/170.5.1323 |
0.32 |
|
| 1992 |
Oksenberg D, Marsters SA, O'Dowd BF, Jin H, Havlik S, Peroutka SJ, Ashkenazi A. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature. 360: 161-3. PMID 1436092 DOI: 10.1038/360161A0 |
0.342 |
|
| 1991 |
Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proceedings of the National Academy of Sciences of the United States of America. 88: 10535-9. PMID 1660140 DOI: 10.1073/Pnas.88.23.10535 |
0.328 |
|
| 1989 |
Ashkenazi A, Ramachandran J, Capon DJ. Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic receptor subtypes. Nature. 340: 146-50. PMID 2739737 DOI: 10.1038/340146A0 |
0.324 |
|
| 1989 |
Ramachandran J, Peralta EG, Ashkenazi A, Winslow JW, Capon DJ. The structural and functional interrelationships of muscarinic acetylcholine receptor subtypes. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 10: 54-7. PMID 2655586 DOI: 10.1002/Bies.950100205 |
0.346 |
|
| 1989 |
Ashkenazi A, Peralta EG, Winslow JW, Ramachandran J, Capon DJ. Functionally distinct G proteins selectively couple different receptors to PI hydrolysis in the same cell. Cell. 56: 487-93. PMID 2492452 DOI: 10.1016/0092-8674(89)90251-1 |
0.343 |
|
| 1988 |
Ashkenazi A, Peralta EG, Winslow JW, Ramachandran J, Capon DJ. Functional role of muscarinic acetylcholine receptor subtype diversity. Cold Spring Harbor Symposia On Quantitative Biology. 53: 263-72. PMID 3254774 DOI: 10.1101/Sqb.1988.053.01.033 |
0.303 |
|
| 1988 |
Peralta EG, Ashkenazi A, Winslow JW, Ramachandran J, Capon DJ. Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature. 334: 434-7. PMID 2841607 DOI: 10.1038/334434A0 |
0.375 |
|
| 1987 |
Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. The Embo Journal. 6: 3923-9. PMID 3443095 DOI: 10.1002/J.1460-2075.1987.Tb02733.X |
0.356 |
|
| 1987 |
Peralta EG, Winslow JW, Peterson GL, Smith DH, Ashkenazi A, Ramachandran J, Schimerlik MI, Capon DJ. Primary structure and biochemical properties of an M2 muscarinic receptor. Science (New York, N.Y.). 236: 600-5. PMID 3107123 DOI: 10.1126/Science.3107123 |
0.338 |
|
| 1987 |
Ashkenazi A, Winslow JW, Peralta EG, Peterson GL, Schimerlik MI, Capon DJ, Ramachandran J. An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover. Science (New York, N.Y.). 238: 672-5. PMID 2823384 DOI: 10.1126/Science.2823384 |
0.356 |
|
| Show low-probability matches. |